Associated Papers
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
35229492 (PubMed )
Supplement: PCMR-35-369-s002.pdf
Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.
Ilcus C et al.
Journal of Personalized Medicine, 2021
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday C et al.
Nature Communications, 2020
32366847 (PubMed )
Supplement: 41467_2020_15768_MOESM7_ESM.xlsx › Supplementary_Data_4
Genetic alterations in primary melanoma in Taiwan.
Sheen YS et al.
The British Journal of Dermatology, 2020
Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients.
Deng Q et al.
Heliyon, 2018
30603682 (PubMed )
Supplement: mmc2.xlsx › Raw_reads_info
Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.
Kamal M et al.
Molecular Oncology, 2018
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
Basse C et al.
Jco Precision Oncology, 2018
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2017
α-Fetoprotein-Producing Hepatoid Gastric Adenocarcinoma With Osteoclast-Like Giant Cells and Neuroendocrine Differentiation: A Case Study With Molecular Profiling.
Wincewicz A et al.
International Journal of Surgical Pathology, 2015
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A et al.
Journal of Dermatological Science, 2013
Select a paper to view details